IDEAYA CEO Cashes Out $985K at 46% Discount to Consensus
IDEAYA's CEO sold $985K in stock at a 46% discount to analyst consensus price targets on October 6, just eight days after the company promoted its R&D chief. The timing and two consecutive EPS misses
IDEAYA CEO Sells $985K as R&D Chief Gets Promoted
NEW YORK, October 11 —
When IDEAYA Biosciences, Inc. (IDYA) elevated its R&D chief on September 28, CEO Yujiro S Hata sold $985K in stock eight days later at prices representing a 46% gap to analyst consensus. Two consecutive EPS misses and a 9% 30-day pullback frame the question: routine planning, or a read on a timeline the bull case has not priced?
- CEO Hata sold 26,338 shares at $37, $38 on October 6 via same-day exercise-and-sell; option exercise cost was $4.31 per share.
- IDEAYA holds $830M in cash against $30M in debt; trailing free cash flow runs -$71M annually.
- Two consecutive EPS misses: -$1.22 vs. -$1.05 estimate last quarter; -$1.11 vs. -$0.98 the quarter prior.
A Sale Timed Against the Upgrade
Per SEC filings, Hata exercised options at $4.31 per share on October 6, then sold all 26,338 resulting shares at $37.39 and $38.26 in open-market transactions, generating gross proceeds of approximately $985K against a $114K exercise cost. The 90-day insider transaction window shows zero purchases and Hata as the sole filer. The sale came eight days after Dr. Michael White was elevated from Chief Scientific Officer to President of Research and Development, a consolidation IDEAYA framed as strengthening pipeline oversight. The exercise-and-sell structure is common for liquidity management, but the timing raises a question the 46% gap to analyst consensus cannot fully answer.
Two Misses After a Blowout Beat
IDEAYA Biosciences develops targeted cancer therapies selected by molecular diagnostics. Its lead asset, Darovasertib, is an oral PKC inhibitor for uveal melanoma; the broader pipeline draws on alliances with GlaxoSmithKline, Pfizer, Gilead, and Novartis. Trailing revenue of $230M comes primarily from partnership milestones, not product sales, which explains a gross margin of -59.7%. Four quarters ago IDEAYA beat consensus by 342%; the two quarters since have both missed, by 13.3% and then 16.2% per the August 4 8-K filing. The burn behind those misses is also what the $830M cash runway was designed to absorb.
| Ticker | Mkt cap | Fwd P/E | 52-wk |
|---|---|---|---|
| IDYA | $3.5B | n/a | +34.9% |
| BCYC | $272M | n/a | -52.1% |
| KYMR | $9.3B | n/a | +87.7% |
| MIRM | $5.6B | n/a | +19.2% |
| IMVT | $6.3B | n/a | +75.6% |
| STOK | $1.6B | n/a | -18.5% |
The Checkpoint Is the Pipeline
IDEAYA's approximately $800M net cash position covers several years of runway at the current -$112M annual operating burn, removing near-term financing risk. What changes the discount story is not the balance sheet but clinical data. A consensus target of $52.75 against a current price of $36.11 implies the market is pricing in a timeline risk that a DCF calculator alone cannot resolve. The next Darovasertib or IDE397 data disclosure is the specific event that either closes that gap or confirms it. Run the free IDEAYA Biosciences, Inc. deep-dive →
Basis Report is independent research for informational purposes. It is not investment advice and not a recommendation to buy or sell any security.
Frequently Asked Questions
When did IDEAYA CEO sell stock?
CEO Yujiro Hata sold 26,338 shares for $985K on October 6 through an exercise-and-sell transaction at prices of $37-$38 per share. He was the only filer in the prior 90 days.
Does IDEAYA have enough cash to fund operations?
IDEAYA holds $830M in cash against $30M in debt, providing roughly $800M in net cash. However, the company's trailing operating cash outflows run -$112M annually and free cash flow is -$71M, limiting runway despite the strong balance sheet.
What are IDEAYA's recent EPS results?
IDEAYA missed consensus estimates in two consecutive quarters: -$1.22 versus -$1.05 expected, and -$1.11 versus -$0.98 expected. This follows a blowout beat four quarters prior, making the recent misses more notable.
What is IDEAYA's lead drug candidate?
Darovasertib is IDEAYA's lead asset, an oral PKC inhibitor in clinical development for uveal melanoma. The company is backed by partnerships with GlaxoSmithKline, Pfizer, Gilead, and Novartis.
What is the consensus price target for IDEAYA stock?
Analysts have a consensus price target of $52.75 against the current trading price of $36.11, implying the market is discounting timeline risk. Clinical trial data disclosure will be the next key event to validate or confirm this gap.
IDEAYA Biosciences CEO Yujiro S Hata sold approximately $985K in stock on October 6, 2026, days after the company elevated its R&D leadership — and as analysts peg the stock roughly 46% below their consensus fair value. A CEO selling at prices analysts call a deep discount forces the question of whether this is routine financial planning or a read on a timeline the model has not fully priced.